These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 23119168)

  • 1. The Value of Combined Large Format Histopathology Technique to Assess the Surgically Removed Breast Tissue following Neoadjuvant Chemotherapy: A Single Institution Study of 40 Cases.
    Ibarra JA
    Int J Breast Cancer; 2012; 2012():361707. PubMed ID: 23119168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conservative surgery after neoadjuvant chemotherapy in patients with operable breast cancer.
    Franceschini G; Di Leone A; Natale M; Sanchez MA; Masett R
    Ann Ital Chir; 2018; 89():290. PubMed ID: 30352955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MRI Identification of the Osseous Extent of Pediatric Bone Sarcomas.
    Thompson MJ; Shapton JC; Punt SE; Johnson CN; Conrad EU
    Clin Orthop Relat Res; 2018 Mar; 476(3):559-564. PubMed ID: 29529641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of neoadjuvant chemotherapeutic response of locally advanced breast cancer by magnetic resonance imaging.
    Abraham DC; Jones RC; Jones SE; Cheek JH; Peters GN; Knox SM; Grant MD; Hampe DW; Savino DA; Harms SE
    Cancer; 1996 Jul; 78(1):91-100. PubMed ID: 8646731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Change in tumor cellularity of breast carcinoma after neoadjuvant chemotherapy as a variable in the pathologic assessment of response.
    Rajan R; Poniecka A; Smith TL; Yang Y; Frye D; Pusztai L; Fiterman DJ; Gal-Gombos E; Whitman G; Rouzier R; Green M; Kuerer H; Buzdar AU; Hortobagyi GN; Symmans WF
    Cancer; 2004 Apr; 100(7):1365-73. PubMed ID: 15042669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Advanced ovarian cancer: primary debulking (PDS) or neoadjuvant chemotherapy (NACT) - still a debate].
    Segev Y; Gemer O; Auslender R; Lavie O
    Harefuah; 2014 Sep; 153(9):527-31, 558. PubMed ID: 25417489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surgical margins in breast-conservation operations for invasive carcinoma: does neoadjuvant chemotherapy have an impact?
    Soucy G; Bélanger J; Leblanc G; Sideris L; Drolet P; Mitchell A; Leclerc YE; Dufresne MP; Beaudet J; Dubé P
    J Am Coll Surg; 2008 Jun; 206(6):1116-21. PubMed ID: 18501808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathologic response and long-term follow-up in breast cancer patients treated with neoadjuvant chemotherapy: a comparison between classifications and their practical application.
    Corben AD; Abi-Raad R; Popa I; Teo CH; Macklin EA; Koerner FC; Taghian AG; Brachtel EF
    Arch Pathol Lab Med; 2013 Aug; 137(8):1074-82. PubMed ID: 23899063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Neoadjuvant Chemotherapy on Breast Cancer Subtype: Does Subtype Change and, if so, How? : IHC Profile and Neoadjuvant Chemotherapy.
    De La Cruz LM; Harhay MO; Zhang P; Ugras S
    Ann Surg Oncol; 2018 Nov; 25(12):3535-3540. PubMed ID: 29981025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histopathologic assessment of tumor regression after neoadjuvant chemotherapy in advanced-stage ovarian cancer.
    Sassen S; Schmalfeldt B; Avril N; Kuhn W; Busch R; Höfler H; Fend F; Nährig J
    Hum Pathol; 2007 Jun; 38(6):926-34. PubMed ID: 17397905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring the response to neoadjuvant chemotherapy in patients with breast cancer using ultrasound scattering coefficient: A preliminary report.
    Dobruch-Sobczak K; Piotrzkowska-Wróblewska H; Klimoda Z; Secomski W; Karwat P; Markiewicz-Grodzicka E; Kolasińska-Ćwikła A; Roszkowska-Purska K; Litniewski J
    J Ultrason; 2019; 19(77):89-97. PubMed ID: 31355579
    [No Abstract]   [Full Text] [Related]  

  • 12. Feasibility of breast conservation surgery in locally advanced breast cancer downstaged by neoadjuvant chemotherapy: a study in mastectomy specimens using simulation lumpectomy.
    Viswambharan JK; Kadambari D; Iyengar KR; Srinivasan K
    Indian J Cancer; 2005; 42(1):30-4. PubMed ID: 15805689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of residual breast carcinoma following neoadjuvant chemotherapy: diffusion-weighted imaging--comparison with contrast-enhanced MR imaging and pathologic findings.
    Woodhams R; Kakita S; Hata H; Iwabuchi K; Kuranami M; Gautam S; Hatabu H; Kan S; Mountford C
    Radiology; 2010 Feb; 254(2):357-66. PubMed ID: 20093508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of Cyclin D1 protein in residual tumor after neoadjuvant chemotherapy for breast cancer.
    Villegas SL; Darb-Esfahani S; von Minckwitz G; Huober J; Weber K; Marmé F; Furlanetto J; Schem C; Pfitzner BM; Lederer B; Engels K; Kümmel S; Müller V; Mehta K; Denkert C; Loibl S
    Breast Cancer Res Treat; 2018 Feb; 168(1):179-187. PubMed ID: 29177689
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incidence and impact of documented eradication of breast cancer axillary lymph node metastases before surgery in patients treated with neoadjuvant chemotherapy.
    Kuerer HM; Sahin AA; Hunt KK; Newman LA; Breslin TM; Ames FC; Ross MI; Buzdar AU; Hortobagyi GN; Singletary SE
    Ann Surg; 1999 Jul; 230(1):72-8. PubMed ID: 10400039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer-aided evaluation of breast MRI for the residual tumor extent and response monitoring in breast cancer patients receiving neoadjuvant chemotherapy.
    Lyou CY; Cho N; Kim SM; Jang M; Park JS; Baek SY; Moon WK
    Korean J Radiol; 2011; 12(1):34-43. PubMed ID: 21228938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of molecular breast imaging in predicting complete tumor response to treatment and residual tumor extent following neoadjuvant therapy.
    Nuvoli S; Galassi S; Gelo I; Rocchitta G; Fancellu A; Serra PA; Madeddu G; Spanu A
    Oncol Rep; 2018 May; 39(5):2055-2062. PubMed ID: 29512735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant treatment with paclitaxel and epirubicin in invasive breast cancer: a phase II study.
    Sarid D; Ron IG; Sperber F; Stadler Y; Kahan P; Kovner F; Ben-Yosef R; Marmor S; Grinberg Y; Maimon N; Weinstein J; Yaal-Hahoshen N
    Clin Drug Investig; 2006; 26(12):691-701. PubMed ID: 17274676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Accuracy of physical examination, ultrasonography, and mammography in predicting residual pathologic tumor size in patients treated with neoadjuvant chemotherapy.
    Chagpar AB; Middleton LP; Sahin AA; Dempsey P; Buzdar AU; Mirza AN; Ames FC; Babiera GV; Feig BW; Hunt KK; Kuerer HM; Meric-Bernstam F; Ross MI; Singletary SE
    Ann Surg; 2006 Feb; 243(2):257-64. PubMed ID: 16432360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphologic effects of neoadjuvant chemotherapy in locally advanced breast cancer.
    Moll UM; Chumas J
    Pathol Res Pract; 1997; 193(3):187-96. PubMed ID: 9198104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.